Theraclone Sciences, Inc. Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A
9/21/2011 9:44:58 AM
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus. This trial is supported in part by Theraclone’s multi-year research and development agreement with Zenyaku Kogyo Co., Ltd. to identify conserved, essential antibody targets and develop candidates for the treatment of pandemic and severe seasonal influenza. TCN-032 was discovered using Theraclone’s I-STAR™ platform.
comments powered by